Physician profile
Jonathan Spencer
NPI 1538163241
$8,617.77
in general payments reported to CMS, 2019-2025
32 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $165 · 2021: $13.92 · 2022: $664 · 2023: $2,225 · 2024: $2,374 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,904 · Travel and Lodging: $659 · Education: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,904.13 |
| Travel and Lodging | $658.84 |
| Education | $521.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,376.50 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Jazz Pharmaceuticals INC. | $1,220.21 | 2019-2025 | |
| Inspire Medical Systems, INC. | $1,149.71 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $1,006.93 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $634.39 | 2019-2025 | Trelegy Ellipta, Nucala |
| Avadel Cns Pharmaceuticals, LLC | $388.68 | 2024-2025 | Lumryz |
| Amgen INC. | $358.20 | 2022-2025 | Tezspire |
| Axsome Therapeutics, INC. | $304.27 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.12 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $194.31 | 2019-2025 | |
| Insmed, INC. | $192.19 | 2023-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $189.47 | 2019-2025 | Prolastin-C Liquid |
| Electromed, INC. | $178.43 | 2019-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $159.19 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $158.89 | 2022-2025 | Glassia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $124.22 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $103.10 | 2023-2025 | Acthar |
| Mylan Specialty L.P. | $85.38 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $66.20 | 2019 | |
| Tactile Systems Technology INC | $63.50 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Genentech USA, INC. | $58.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $57.99 | 2019-2020 | |
| Resmed Corp | $48.15 | 2025 | |
| Verona Pharma, INC. | $39.43 | 2025 | Ohtuvayre |
| 3b Medical, INC. | $36.58 | 2024-2025 | Luna |
| Idorsia Pharmaceuticals US INC | $31.62 | 2023 | Quviviq |
| Baxter Healthcare | $26.38 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Astellas Pharma US INC | $23.97 | 2024 | Cresemba |
| United Therapeutics Corporation | $20.09 | 2024 | Tyvaso |
| Sanofi Pasteur INC. | $20.07 | 2023 | |
| Viatris Specialty LLC | $17.58 | 2025 | Yupelri |
| Lilly USA, LLC | $16.87 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.